Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Apellis Pharmaceuticals, Inc. < Previous 1 2 Next > Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN August 08, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 06, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results August 01, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results July 18, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting July 09, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU June 28, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA) June 10, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference June 05, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress May 24, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street May 14, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results May 07, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference May 06, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting May 01, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA) April 26, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results April 23, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 04, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference April 01, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor March 11, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 06, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results February 27, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Present at Upcoming Investor Conferences February 26, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results February 20, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 06, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application January 26, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues January 08, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 05, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference December 28, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union December 14, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting December 11, 2023 From Apellis Pharmaceuticals, Inc. Via GlobeNewswire Tickers APLS < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.